At the European Cancer Congress (ECC) 2015, Dirk Schadendorf, MD, PhD, of Universitätsklinikum Essen, Essen, Germany, discusses the advances in the understanding of BRAF-mutant melanoma biology, which involves the constitutive activation of the MAPK pathway, that have led to the development of new targeted therapies for patients with metastatic disease.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Advertisement